Overview

A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to assess the safety, tolerability, pharmacokinetics and efficacy of VAL401 in the treatment of patients with locally advanced or metastatic non-small cell lung adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
ValiSeek Limited
Treatments:
Risperidone